Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The EC approved Libtayo – a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells – based on data from the global open-label, multi-centre phase 3 EMPOWER ...

Monoclonal antibody: lab-made protein targeting cancer cells ... All received solnerstotug (3 mg/kg or 15 mg/kg) with Libtayo. Eleven had not yet reached the first baseline scan, and eight ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a conditionally active monoclonal antibody targeting VISTA.

SAFEbody is a masking technology that aims to ensure that antibodies are only activated ... its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), which still has modest sales ...

Libtayo, an immunotherapy for cancer ... lung cancer and other solid tumors, biospecific antibodies for blood cancers, and Factor XI antibodies for blood clot prevention, among others.

A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma.